400 mg Rifamycin SV dosage + 800 mg Rifamycin SV dosage + 1200 mg Rifamycin SV dosage

Phase 2Completed

0 watching 0 views this week⚡ Active

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Infectious Diarrhoea

Conditions

Infectious Diarrhoea

Trial Timeline

Feb 1, 2008 → Jul 1, 2008

NCT ID

NCT03447821

About 400 mg Rifamycin SV dosage + 800 mg Rifamycin SV dosage + 1200 mg Rifamycin SV dosage

400 mg Rifamycin SV dosage + 800 mg Rifamycin SV dosage + 1200 mg Rifamycin SV dosage is a phase 2 stage product being developed by Cosmo Pharmaceuticals for Infectious Diarrhoea. The current trial status is completed. This product is registered under clinical trial identifier NCT03447821. Target conditions include Infectious Diarrhoea.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03447821	Phase 2	Completed	Feb 1, 2008	Jul 1, 2008	Infectious Diarrhoea

Competing Products

20 competing products in Infectious Diarrhoea

See all competitors

Product	Company	Stage	Hype Score
levofloxacin	Johnson & Johnson	Phase 2/3	65
Levofloxacin	Johnson & Johnson	Phase 3	77
Adalimumab	AbbVie	Approved	85
Acalabrutinib + Rabeprazole	AstraZeneca	Phase 1	33
Cefepime + Ceftolozane + Meropenem + Piperacillin-Tazobactam + Tazobactam	Merck	Phase 2	52
Daptomycin + Standard of Care (SOC)	Merck	Approved	85
MK-7655 + Imipenem + Cilastatin + Caffeine + Midazolam + Omeprazole	Merck	Phase 1	33
TR-701 200 mg + TR-701 300 mg + TR-701 400 mg	Merck	Phase 2	52
Tedizolid Phophate + Antibiotic comparator + Aztreonam + Metronidazole	Merck	Phase 3	77
FTY720 + Oral Corticosteroid	Novartis	Phase 2	52
Daptomycin + Vancomycin + Teicoplanin	Novartis	Phase 3	77
PTK 0796 + linezolid + moxifloxacin	Novartis	Phase 3	77
LFG316 + Conventional Therapy	Novartis	Phase 2	52
AIN457 + Placebo	Novartis	Phase 3	77
AIN457 + AIN457 + AIN457 + Placebo	Novartis	Phase 3	77
AIN457 + AIN 457 + AIN457	Novartis	Phase 2	52
valacyclovir	Roche	Phase 1/2	41
Filgotinib + Placebo to match filgotinib + Prednisone	Gilead Sciences	Phase 2	51
Tigecycline + vancomycin with aztreonam	Pfizer	Phase 3	76
Tigecycline	Pfizer	Approved	84

Other Products from Cosmo Pharmaceuticals

Methylene Blue MMX 25 mg modified release tabletsPhase 2

Rifamycin SV 600mg t.i.d. + Rifamycin SV b.i.d. + Placebo + Placebo t.i.d.Phase 2

CB-03-10Phase 1